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Humoral Autoimmune Responses to the Squamous
Cell Carcinoma Antigen Protein Family in Psoriasis
Rana G. El-Rachkidy1, Helen S. Young2, Christopher E.M. Griffiths2 and Richard D.R. Camp1
Substantial evidence indicates that psoriasis is a T-lymphocyte-mediated autoimmune disease. However,
longstanding data also indicate IgG and complement deposition in upper epidermis of psoriasis plaques. This
led us to propose that autoantigen–autoantibody interactions in the skin may also be of pathogenic importance.
Here, we have confirmed the presence of IgG in upper lesional epidermis and used high-resolution two-
dimensional immunoblotting of extracts from this tissue, and laser desorption mass spectrometry of tryptic
peptides, to define a series of epidermal proteins that bind IgG from psoriatic serum. The most prominent of
these autoantigens are homologues of the serpin, squamous cell carcinoma antigen (SCCA), the other
autoantigens identified including arginase 1, enolase 1, and keratin 10. Blood levels of IgG autoantibodies that
bind to SCCA proteins were significantly higher in psoriasis than healthy controls (P¼ 0.005), but were not
detectable in sera from patients with active atopic dermatitis. To our knowledge, SCCA proteins have not
previously been described as autoantigenic in animals or humans and form complexes with IgG that are
associated with complement deposition. These findings expose potentially pathogenic humoral immunologic
events and thus possible therapeutic targets in psoriasis.
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INTRODUCTION
The skin lesions or plaques of psoriasis are characterized by
epidermal hyperplasia and infiltrates of leukocytes including
neutrophils and homing receptor-positive T lymphocytes
(Gudjonsson et al., 2004). The disease can be provoked by
activated T cells in xenograft models (Boyman et al., 2004) and
therapies that target T cells are effective (Kupper, 2003),
although potentially toxic in the long term. Analysis of T-cell
receptor diversity indicates oligoclonal infiltrates in many, if not
all psoriatic lesions, and thus an antigen-driven process
(Menssen et al., 1995; Vekony et al., 1997). These and other
findings, including association with HLA-Cw*0602 and inflam-
matory arthropathy, indicate that psoriasis is an autoimmune
disease that occurs in genetically predisposed individuals
(Gudjonsson et al., 2004). Although these findings show that
T-cell-mediated events are of key pathogenic importance, it was
reported more than 30 years ago that there is more IgG bound
in vivo in the upper epidermis and stratum corneum of psoriatic
lesions than in a variety of other inflammatory and hyperker-
atotic skin diseases (Jablonska et al., 1975). Reports also describe
the presence of products of complement activation in the surface
stratum corneum of plaques, including C5a/C5a des arg
(Schro¨der and Christophers, 1986) and C5-9/membrane attack
complex (Takematsu and Tagami, 1992). These data suggest that
antigen–antibody interactions, which provoke complement
activation, are of pathogenic relevance in psoriasis.
A previous attempt to identify autoantigens in psoriatic lesions
by screening cDNA expression libraries with psoriatic serum
defined three putative autoantigens, including heterogeneous
nuclear ribonucleoprotein-A, keratin 13 (K13), and a previously
uncharacterized protein (Jones et al., 2004). Assay of IgG titers
was complicated by phage reactivity requiring extensive pre-
clearing of serum, and these titers were no different in psoriatic
and control sera. Apart from this, there have been no reports of
the systematic analysis of psoriatic lesional proteins that bind IgG.
The rapidly shed and readily harvested surface stratum corneum
of psoriatic lesions is a useful source of biologically active
molecules that occur in the underlying viable epidermis.
Analyses of extracts of this material have previously allowed
demonstrations of the in vivo production of leukotriene B4 (Brain
et al., 1984), IL-8 (Schro¨der and Christophers, 1986; Fincham
et al., 1988; Gearing et al., 1990), tumor necrosis factor-a
(Ettehadi et al., 1994), and b-defensins (Harder et al., 1997,
2001). We have therefore used stratum corneum as a source of
lesional proteins to define IgG-reactive autoantigens in psoriasis.
RESULTS
IgG deposition in the upper epidermis of psoriasis lesions
Lesional stratum corneum was obtained from an informed,
consenting volunteer with extensive, untreated chronic
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plaque psoriasis, and aqueous extracts were prepared as
described in Materials and Methods. Total proteins in
supernatants of these extracts were used to coat microtiter
plate wells, and the presence of IgG was demonstrated by the
use of alkaline phosphatase (AP)-labeled goat anti-human IgG
either in the absence of added serum or after the addition of
100-fold diluted, pooled psoriatic serum (Figure 1). IgG was
shown in stratum corneum extracts, and the amount of
detected IgG could not be enhanced by the prior addition of
psoriatic serum, which suggested that target molecules were
substantially bound by IgG in vivo. This supports the
longstanding findings of Jablonska et al. (1975), who reported
IgG deposition in upper lesional epidermis by the use of
direct immunofluorescence, which could not be usually
enhanced by prior incubation of sections with psoriatic
serum.
Identification of IgG-reactive proteins in the stratum corneum
of psoriasis lesions
Protein extracts were prepared by homogenization of
psoriatic lesional stratum corneum and further solubilized
by the addition of urea, thiourea, and non-ionic detergent. In
these extracts, constituent proteins were successively sepa-
rated by high-resolution isoelectric focusing and denaturing
PAGE. Two-dimensional gels were prepared in the same
electrophoresis tank and were either stained with colloidal
Coomassie blue (Candiano et al., 2004) (Figure 2a) or
electroblotted onto nitrocellulose and incubated with pooled
psoriatic serum (1:200) (Figure 2b) or pooled serum from age-
and sex-matched healthy controls (Figure 2c). Bound IgG,
detected with AP-labeled anti-human IgG, showed the
presence of a series of IgG-reactive proteins that were more
numerous on blots incubated with psoriatic sera than with
control sera. Spots labeled 1–11 (Figure 2b and c) corre-
sponded with similarly numbered proteins on the Coomassie-
stained gel (Figure 2a). Appropriate Coomassie-stained
protein spots were cut from the gel, subjected to trypsin
digestion, and tryptic peptides analyzed by MALDI-TOF
(matrix-assisted, laser desorption ionization-time of flight)
mass spectrometry (Shevchenko et al., 1996; Bonetto et al.,
1997). The proteins identified included enolase 1, squamous
cell carcinoma antigen (SCCA), SCCA 1, SCCA 2, SCCA 2b,
arginase 1, and K10, as indicated in the lower panel of
Figure 2.
Quantification of SCCA- and K10-reactive IgG in blood samples
from psoriasis patients and controls
In repeated two-dimensional immunoblots of separated
stratum corneum proteins, incubated with sera from
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Figure 1. IgG is present in the stratum corneum (SC) of psoriasis lesions. The
ELISA used AP-labeled Ab to detect IgG in aqueous stratum corneum extract,
with and without prior addition of pooled, 100-fold diluted serum from eight
psoriasis patients. The lowest curve shows optical readings in the presence
of AP substrate alone, without added AP-labeled Ab. This indicates that there
is no significant endogenous AP activity in the stratum corneum samples.
Each point represents the mean of quadruplicate estimations.
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Figure 2. IgGs in pooled serum from psoriasis patients recognize a greater range of proteins in lesional stratum corneum extract than pooled serum from
age- and sex-matched controls. (a) Coomassie-stained two-dimensional gel showing separated proteins. Blots of 2-dimensional gels run in parallel were
incubated with pooled serum (1:200 dilution) from eight patients with psoriasis (b) and eight age- and sex-matched healthy controls (c), and IgG-binding proteins
localized with AP-labeled anti-IgG. IgG-reactive proteins that corresponded with Coomassie-stained spots in panel a were identified by MALDI-TOF mass
spectrometry and are labeled 1–11. The identities of these proteins are indicated in the lower panel. Similar results to those shown in panels a–c were obtained
in a second experiment with different stratum corneum extract and pooled serum samples.
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individual patients with chronic plaque psoriasis, serum IgGs
reactive with SCCA proteins (spots 3, 4, 5, 8 and 9 in
Figure 2) were consistently observed to be the most
abundant. The measurement of titers of SCCA-reactive IgG
in individual sera from patients with chronic plaque psoriasis
and controls was therefore attempted by ELISA. Initial work
showed that the use of ELISA with Escherichia coli-derived
recombinant proteins as substrates gave false-positive read-
ings (data not shown). This was likely to be a result of
reactivity of serum IgGs with trace amounts of vector
contaminants, a problem that has been recently recognized
as leading to falsely high autoantibody titers in such ELISAs
(Schmetzer et al., 2005). Attempts to eliminate vector
contaminants from the ELISA by anchoring recombinant
SCCA substrate to microtiter plate wells coated with murine
monoclonal SCCA antibody (Ab) were also unsuccessful,
because a significant percentage of human sera contained
IgG that was reactive with the anchoring murine Ab (data not
shown).
Large numbers of high-resolution two-dimensional blots of
lesional stratum corneum proteins, which provided the
separations shown (Figure 2), were therefore incubated with
individual serum or plasma samples from patients with
chronic plaque psoriasis and controls (1:200 dilutions).
Bound IgGs were detected with AP-labeled goat anti-human
IgG Ab, and the intensities of the labeled spots co-migrating
with individual SCCA proteins were determined by densito-
metry. The intensity values for each SCCA spot were
normalized to a standard, as described in Materials and
Methods. Levels of SCCA-reactive IgG, expressed in arbitrary
units (Figure 3a), were significantly higher in blood samples
from patients with chronic plaque psoriasis (42.1±7.7,
n¼34) than in samples from healthy controls (18.8±3.9,
n¼28; means±SEM, P¼0.005, Mann–Whitney test). There
was no correlation between SCCA-specific IgG levels and the
clinical severity of psoriasis as determined by the psoriasis
area and severity index (Fredricksson and Pettersson, 1978),
nor any significant difference between the levels in patients
who were HLA-Cw*0602-positive or -negative (data not
shown). Levels of K10-reactive IgG were also quantified, in
view of the preliminary evidence that these levels might be
higher in blood samples from patients than controls (Figure
2b and c). However, densitometric analysis of large numbers
of two-dimensional immunoblots showed that blood levels of
K10-reactive IgG in patients (23.1±9.1AU (arbitrary units),
n¼33) were not significantly different from those in controls
(15.1±4.7, n¼23; means±SEM, P¼ 0.85, Mann–Whitney
test; Figure 3b).
Association of SCCA–IgG interaction with complement
deposition and specificity of SCCA autoantibodies to psoriasis
To explore the potential pathogenicity of SCCA–IgG interac-
tions, a two-dimensional blot of lesional stratum corneum
extract was incubated with serum (1:20 dilution) from a
psoriasis patient containing a high level of SCCA-binding IgG
and deposition of the complement component C3 demon-
strated with C3c Ab and autoradiography (Figure 4a). The
blot was then stripped, re-incubated with the same serum
(1:200 dilution), and bound IgG detected with horseradish
peroxidase-labeled anti-IgG and further autoradiography
(Figure 4b). This showed deposition of C3 that colocalized
with IgG binding at SCCA spots. Two-dimensional immuno-
blots of proteins from psoriatic stratum corneum were also
incubated with pooled serum from five patients with active
atopic dermatitis. As shown in Figure 4c, sera from these
patients did not contain detectable SCCA-reactive IgG.
DISCUSSION
In this study, we confirmed the in vivo deposition of IgG in
the upper epidermis of the chronic plaques of psoriasis. We
then defined a series of IgG-binding autoantigens in psoriatic
epidermis, the most prominent of which were the SCCA
family. SCCA 1 is a member of the ovalbumin-serpin group
of protease inhibitors and is a truncated version of SCCA.
Both are cysteine protease inhibitors, whereas their
homologue SCCA 2 inhibits serine proteases (Masumoto
et al., 2003). SCCA 1 and 2 are expressed by keratinocytes
in vitro (Hamada et al., 2001), and SCCA protein is both
overexpressed in lesional epidermis as shown by immuno-
histochemistry, in situ hybridization, and immunoelectron-
microscopy (Takeda et al., 2002) and is present in increased
levels in the serum of patients with psoriasis (Duk et al.,
1989; Takeda et al., 2002). Microarray analysis has also
shown remarkably upregulated expression of the SCCA 1 and
2 genes (SERPINB3 and SERPINB4) in psoriatic lesional
versus non-lesional skin (Haider et al., 2006). SCCA 2b is
another homologue of SCCA 1 (Suminami et al., 2001), but its
biologic properties have not been described nor has it been
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Figure 3. Levels of SCCA-reactive IgG but not keratin 10-reactive IgG are
higher in blood samples from patients with chronic plaque psoriasis than in
matched healthy controls. The two sets of values for SCCA-reactive IgG (a)
derived by densitometry after two-dimensional immunoblotting with serum or
plasma samples from psoriasis patients (n¼ 34) and matched healthy controls
(n¼28) were significantly different (P¼0.005). In contrast (b), levels of
keratin 10-reactive IgG in blood samples from psoriasis patients (n¼ 33) and
matched controls (n¼23) were not significantly different (P¼ 0.85). The
arrowed values show the results obtained with the standard serum sample that
was included in each batch of six analyses and used to normalize data, as
described in Materials and Methods.
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previously reported as a product of epidermis. Importantly,
we have not found any previous descriptions of autoanti-
bodies directed against the SCCA family in any setting, either
in humans or animals.
Arginase 1, which catalyzes the metabolism of arginine to
urea and ornithine, is also overexpressed in the epidermis of
psoriatic lesions (Bruch-Gerharz et al., 2003), but we have
found only one report of autoantibodies against this enzyme,
that is, in human autoimmune hepatitis (Kimura et al., 2000).
The glycolytic enzyme enolase 1 has been described as an
autoantigen in several settings including Behcet’s disease
(Lee et al., 2003) and systemic lupus erythematosus (Kemp
et al., 2002), but to our knowledge not previously in psoriasis.
Autoantibodies against mixed epidermal keratins are well
recognized both in normal and psoriatic sera (Aoki et al.,
1989), but to our knowledge, a pathogenic role for these Abs
has not been established and autoantibodies that specifically
recognize K10 have not been reported previously. We have
shown that K10 autoantibodies are detectable in normal and
psoriatic blood samples, but the levels in samples from the
two sources are not significantly different. It was of interest
that no IgG-binding microbial proteins were identified in this
study, particularly because organisms such as Staphylococ-
cus aureus are known sometimes to colonize the surface of
psoriasis lesions (Payne, 1967).
The measurement of SCCA Abs in human serum was not a
straightforward procedure in this study in view of the
described nonspecific serum IgG reactivity, when a recom-
binant form of SCCA was used as substrate in ELISAs either in
the presence or absence of anchoring murine SCCA Ab. We
therefore proceeded to analyze the intensities of Abs reactive
with human epidermal SCCA proteins in large numbers of
two-dimensional high-resolution immunoblots. This strategy
was supported by the knowledge that there are numerous
potential glycosylation and phosphorylation sites in SCCA
proteins and that recombinant forms may therefore not
possess the same IgG reactivity as human proteins produced
in vivo. However, the disadvantage of our strategy was the
need to use denatured human proteins in two-dimensional
immunoblots.
Densitometry of immunoblots showed that blood levels of
SCCA Abs were significantly higher in patients with chronic
plaque psoriasis than in controls (Figure 3a). Some healthy
control subjects also showed detectable levels of these Abs,
which allows the speculation that interactions between
serum IgG and SCCA, and possibly some of the other
autoantigens identified, may be an early event in disease
pathogenesis once local homeostasis is altered in predisposed
individuals. The effects of autoantibody binding on the
function of SCCA proteins have not yet been explored.
Whether this binding may interfere with their protease
inhibitory function and thus enhance inflammation by
allowing uncontrolled protease activity is, to our knowledge,
currently not known. However, we have demonstrated
complement deposition in association with SCCA–IgG inter-
action, which suggests that the interaction is pathogenic.
The specificity of anti-SCCA IgG autoantibodies to
psoriasis has only been investigated to a limited extent in
this study. We showed that these Abs were not detectable in
pooled sera of patients with active atopic dermatitis, in spite
of the fact that elevated levels of SCCA protein have been
found in the affected skin and serum of patients with this skin
disease (Mitsuishi et al., 2005). Further study is required to
determine the specificity of SCCA IgG Abs to psoriasis. SCCA
protein is expressed by squamous cell carcinomas, and serum
levels are widely used as a tumor marker (Kato, 1996); and it
would be of particular interest if SCCA proteins are shown to
be relevant tumor antigens in these cancers.
In conclusion, to our knowledge, these findings define a
potentially pathogenic immune response directed against
SCCA proteins, which have not been reported previously.
Whether this is an early pathogenic event in psoriasis or one
that occurs as a consequence of the exposure of a normally
sequestered protein during plaque development and thus
enhances the inflammatory response as a secondary phe-
nomenon remains to be determined. The findings also suggest
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Figure 4. Complement deposition is associated with SCCA–IgG interaction, and SCCA-reactive IgG is absent in sera from patients with active atopic
dermatitis. (a) A blot of psoriatic stratum corneum-derived SCCA proteins separated by two-dimensional electrophoresis was incubated with a 20-fold dilution
of a psoriatic serum sample containing a high level of SCCA-reactive IgG. C3 deposition was shown by autoradiography after incubation with C3c Ab. (b) The
same blot was stripped, re-incubated with a 200-fold dilution of the same serum, and IgG deposition shown with horseradish peroxidase-labeled anti-IgG
and further autoradiography. The pattern of C3 deposition on SCCA proteins corresponds with the pattern of IgG binding. (c) A blot of psoriatic stratum
corneum-derived SCCA proteins separated by high-resolution two-dimensional electrophoresis and incubated successively with a 200-fold dilution of
pooled serum from five patients with active atopic dermatitis and AP-labeled anti-IgG shows no IgG-reactive proteins. Each blot (a–c) is enlarged from
original size by 150%, and the area occupied by SCCA proteins illustrated.
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that therapeutic blockade of complement activation in
psoriasis is worthy of further study.
MATERIALS AND METHODS
Subjects and samples
This study was approved by the local research ethics committee and
was conducted in accordance with the Declaration of Helsinki
Principles. Written informed consent was obtained from each donor.
Patients with chronic plaque psoriasis and atopic dermatitis met
standard diagnostic criteria, had active, moderate-to-severe skin
disease, and had not received systemic therapy or UV irradiation for
their skin disease for at least 2 months before venesection. Patients
with psoriasis included 15 females and 19 males aged 22–66 years,
with a mean psoriasis area and severity index (Fredricksson and
Pettersson, 1978) of 13.9±6.8 (SD). Control subjects were healthy
volunteers aged 23–66 years, including 14 females and 14 males.
Venous blood samples were obtained from each subject, allowed to
clot in glass test tubes, and serum was removed and centrifuged to
deplete cells. In some cases, venous blood was mixed with heparin
and plasma was obtained after centrifugation. Serum and plasma
samples were stored at 801C in aliquots. Desquamating stratum
corneum was removed by gentle abrasion with a scalpel blade from
the surface of skin lesions of a 60-year-old male volunteer with
moderately severe psoriasis, which had not received topical
treatment for at least 2 weeks and had never been treated with
systemic agents. Recovered tissue was stored at 201C in aliquots.
Tissue extraction, ELISA, and electrophoresis
Stratum corneum samples were fragmented in ice-cold phosphate-
buffered saline (PBS) with 0.5mM phenylmethylsulfonyl fluoride and
1mM EDTA in a ground glass homogenizer. In experiments to
demonstrate IgG in these extracts, homogenate was centrifuged at
12,000 g for 5minutes, and supernatant added to wells of Maxisorb
microtiter plates (Nunc, Roskilde, Denmark) in varying amounts up
to a maximum of 2mg total protein per well. Coated wells were
washed five times with PBS containing 0.05% Tween 20 (PBS/T),
blocked with 5% skimmed milk powder in PBS for 2 hours at 371C,
and then again washed five times with PBS/T. Some coated wells
were also treated with pooled, diluted serum from eight patients with
psoriasis. The pooled serum was diluted 100-fold in PBS containing
1% milk powder and left in wells at 37 1C for 2 hours before washing
with PBS/T as above. AP-labeled goat anti-human IgG (product code
A 3188; Sigma, Poole, UK) diluted 1:4,000 with 1% skimmed milk
powder in PBS/T (PBS/T/M) was then added for 90minutes at 37 1C,
wells were again washed five times with PBS/T, substrate p-
nitrophenyl phosphate (Sigma) added according to the supplier’s
instructions, and optical densities read at 405 nm. Before two-
dimensional electrophoresis, aliquots of stratum corneum homo-
genate prepared as described above were solubilized with equal
volumes of buffer containing 7M urea, 2 M thiourea, and 4% CHAPS
(3-[(3-cholamidopropyl)-dimethylammonio]-1-propane sulfonate)
kept at room temperature for 20minutes with occasional agitation.
After centrifugation at 12,000 g for 5minutes, 50ml aliquots were
applied to Pierce spin desalting minicolumns (product code 89866;
Perbio, Cramlington, UK) in accordance with the manufacturer’s
instructions. Eluates were mixed with rehydration buffer containing
the above concentrations of urea, thiourea, and CHAPS, 2%
ampholytes (Bio-Rad, Hemel Hempstead, UK), and 100mM
DeStreak reagent (Amersham, Little Chalfont, UK) to a final protein
concentration of 1 mg ml1. Batches of proteins (300 mg) were
separated on 17 cm (pH 3–10) ReadyStrip IPG strips in a Protean
isoelectrofocusing cell (Bio-Rad). Strips were equilibrated in
accordance with the manufacturer’s instructions and laid on up to
six 20 cm 20 cm 1mm 12% acrylamide gels, which were run in
parallel in an Ettan DALTsix electrophoresis unit (Amersham) under
denaturing conditions.
Immunoblotting and protein identification
Gels run in parallel were either stained directly with Coomassie blue
G250 (Candiano et al., 2004) or electroblotted onto 20 20 cm
Hybond-ECL nitrocellulose membranes (Amersham). Membranes
were blocked with 5% skimmed milk powder in PBS at 4 1C
overnight, washed four times in PBS/T, and then incubated with
either pooled or individual serum or plasma samples (diluted 1:200)
with PBS/T/M for 2 hours at room temperature. After four washes in
PBS/T, membranes were incubated with AP-labeled anti-human IgG
(Sigma) (diluted 1:4,000) with PBS/T/M for 90minutes at room
temperature. After a further four washes, membranes were treated
with substrate BCIP/NBT (5-bromo-4-chloro-3-indolyl phosphate/
nitro blue tetrazolium chloride; Sigma) in accordance with the
supplier’s instructions. Coomassie blue-stained protein spots of
interest were excised from gels, placed in Eppendorff tubes with
20 ml water and subsequently subjected to tryptic digestion, and
analysis by MALDI-TOF mass spectrometry, as described previously
(Shevchenko et al., 1996; Bonetto et al., 1997). In experiments to
detect deposition of complement components, a nitrocellulose blot
of two-dimensionally separated psoriatic stratum corneum proteins
was incubated at room temperature for 2 hours with serum (1:20
dilution in PBS/T/M) from a psoriasis patient, followed by four
washes in PBS/T, and then incubation for 90minutes at room
temperature with rabbit anti-human C3c Ab (Dako, Ely, UK) diluted
1,000-fold in PBS/T/M. After washing, the membrane was incubated
for 90minutes at room temperature with horseradish peroxidase-
labeled goat anti-rabbit Ab (Sigma) diluted 4,000-fold in PBS/T/M,
washed again and incubated with ECL substrate (Amersham) in
accordance with the manufacturer’s instructions. After autoradio-
graphy, the blot was stripped, re-incubated with the same serum
diluted 1:200 in PBS/T/M, and bound IgG detected with horseradish
peroxidase-conjugated anti-human IgG (Sigma) and further auto-
radiography.
Data analysis
For quantification of IgG levels reactive with the SCCA and K10
proteins separated by two-dimensional electrophoresis, immuno-
blots were prepared in sets of six from gels run in parallel in the same
six-gel electrophoresis tank. Each blot was incubated with a 200-fold
diluted serum or plasma sample from an individual donor, as
described above, one of the sera always being a standard high titer
serum from the same donor. BCIP/NBT immunoblot signals were
quantified by densitometry (G5-710 instrument with Quantity One
software; BioRad). Briefly, the total signal intensity inside a defined
boundary drawn around each selected spot was adjusted by
automated local background subtraction in accordance with the
manufacturer’s user guide. The adjusted intensity of each SCCA spot
(numbered 3, 4, 5, 8, and 9 in Figure 2) was expressed as a
percentage of the adjusted intensity of the corresponding spot
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generated with the standard serum. The normalized SCCA BCIP/NBT
spot intensities were then summed and a mean value obtained for
each serum or plasma sample. The adjusted intensities of the two
K10 spots (numbered 10 and 11 in Figure 2) were also determined as
above. The derived spot intensities were expressed as arbitrary units,
and the significance of differences between values obtained with
serum or plasma samples from psoriasis patients and healthy controls
was analyzed by the Mann–Whitney test for non-parametric data.
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